AI assistant
AbbVie Inc. — Director's Dealing 2024
Mar 1, 2024
29755_dirs_2024-03-01_fd527705-65e8-4eab-b4b7-6e3d73f477d6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2024-02-28
Reporting Person: Siatis Perry C (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-28 | Common Stock, $0.01 par value | F | 7885 | $178.99 | Disposed | 20288 | Direct |
| 2024-02-29 | Common Stock, $0.01 par value | S | 6504 | $177.05 | Disposed | 13784 | Direct |
| 2024-02-29 | Common Stock, $0.01 par value | S | 3387 | $178.04 | Disposed | 10397 | Direct |
Footnotes
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.51 to $177.43, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 1, 2023.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.51 to $177.88, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.